Septo-optic dysplasia spectrum

Septo-optic dysplasia (SOD), also known as de Morsier syndrome, is a rare congenital disorder characterized by a classic triad of features: optic nerve hypoplasia (underdevelopment of one or both optic nerves), midline brain defects (most commonly absence or hypoplasia of the septum pellucidum and/or corpus callosum), and pituitary hormone deficiencies (hypopituitarism). The diagnosis is typically made when at least two of these three features are present. The condition is considered a spectrum disorder because the severity and combination of features vary widely among affected individuals. The visual system is commonly affected, with optic nerve hypoplasia leading to varying degrees of visual impairment, ranging from mild reduction in visual acuity to near-complete blindness. Nystagmus (involuntary eye movements) is frequently observed. Hypothalamic-pituitary dysfunction can result in deficiencies of growth hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, antidiuretic hormone, and gonadotropins, leading to growth failure, hypothyroidism, adrenal insufficiency, diabetes insipidus, and delayed or absent puberty. Some patients also present with developmental delays, intellectual disability, and seizures, particularly when additional brain malformations such as schizencephaly or cortical dysplasia are present. Most cases of septo-optic dysplasia occur sporadically, though rare familial cases have been associated with mutations in genes such as HESX1, SOX2, SOX3, and OTX2, among others. Environmental risk factors including young maternal age and prenatal exposure to certain substances have also been suggested. Treatment is supportive and symptom-directed, focusing on hormone replacement therapy for pituitary deficiencies, ophthalmologic management for visual impairment, and developmental support services including physical, occupational, and speech therapy. Early identification and treatment of hormonal deficiencies, particularly cortisol deficiency, is critical as adrenal crisis can be life-threatening.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Septo-optic dysplasia spectrum